Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug is expensive, and many people can't get it yet.

Novavax Inc. closed 60.47% below its 52-week high of $17.81, which the company achieved on July 26th.

The stock's fall snapped a three-day winning streak.

The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...

FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid ...

While both the Novavax vaccine and the newest generation of the mRNA Moderna vaccines had been signed off on by about 30 FDA vaccine officials, Prasad ended up writing overrides for each, restricting ...

If, however, the Novavax BLA represents a new normal process at the FDA, it portends potential trouble ahead for COVID-19 vaccines—and the nation’s ability to weather the upcoming respiratory season,” ...

Analyst Price Forecast Suggests 141.82% Upside As of June 2, 2025, the average one-year price target for Novavax is $17.00/share. The forecasts range from a low of $9.09 to a high of $26.25.